Mylan’s Rollout Of Herceptin Biosimilar In India To Begin Its March Into Emerging Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
Experience gathered from the launch of trastuzumab copies in India will help position Mylan in several other emerging markets, execs tell PharmAsia News. Meanwhile, the global generics giant also inks a deal to become the exclusive partner for Gilead’s branded medicines business in India.